Clinical trial
clinical trial
Randomized phase II trial of temsirolimus (NCIi-supplied agent, NSC # 683864, IND # 61010) or the combination of hormonal therapy plus temsirolimus in women with advanced, persistent, or recurrent endometrial carcinoma
Intervention
Drug intervention
Intervention Type
drug intervention
has_intervention
Tamoxifen citrate
drug intervention
Tamoxifen citrate
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Megestrol acetate
drug intervention
Megestrol acetate
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Temsirolimus
drug intervention
Temsirolimus
Intervention
intervention
planned process
planned process
process
occurrent
entity
Contact
has contact
has_contact
Berenberg, Jeffrey
PI
has PI
has_PI
Topic
has topic
has_topic
endometrial cancer
Funded by
funded by
funded_by
Gynecologic Oncology Group
Phase
Phase 2 clinical trial
has phase
has_phase
Phase 2
Performed by
human study performed by
human_study_performed_by
Clinical Protocol & Data Management Shared Resource
http://www.clinicaltrials.gov/ct2/show/NCT00729586?term=GOG-0248&rank=1
ClinicalTrials.gov url
ClinicalTrials.gov url
CTurl
http://www.cancer.gov/clinicaltrials/search/view?cdrid=609740&version=healthprofessional
Website(s)
has URL
has_url
Antineoplastic combined chemotherapy protocols
Additional Topic(s)
has_subject_area
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol and tamoxifen may fight endometrial cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether temsirolimus is more effective when given alone or together with megestrol and tamoxifen in treating endometrial cancer.
This randomized phase II trial is studying temsirolimus to see how well it works with or without megestrol and tamoxifen in treating patients with advanced, persistent, or recurrent endometrial cancer.
Resource Description
resource_description
Females with histologically confirmed endometrial carcinoma.
Study Population
study population
has_study_population
2011-06-29T17:43:01.038-05:00
awendicke (Annemarie Wendicke)
2011-09-23T11:15:46.456-05:00
workflow state
Published
nvasilevsky
cpealer
Interventional study
Research project
research project
Human Study
human study
human study
planned process
planned process
Quantitative human study
process
occurrent
entity